resTORbio

resTORbio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for aging-related diseases. The company was founded in early 2017 by PureTech Health and supported by Novartis, obtaining licensed compounds from Novartis that inhibit targets related to the mTOR pathway (such as the TORC1 inhibitor RTB101). resTORbio’s mission is to become a biopharmaceutical company dedicated to treating aging-related diseases. Initially, its primary focus is on developing innovative TORC1 inhibitors licensed from Novartis, targeting immunosenescence — age-related diseases caused by the structural and functional decline of the immune system as people grow older.